```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSPTARHH1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *  Welcome to STN International  * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  JAN 08  CHEMLIST enhanced with New Zealand Inventory of Chemicals
 NEWS  3  JAN 16  CA/CAplus Company Name Thesaurus enhanced and reloaded
 NEWS  4  JAN 16  IPC version 2007.01 thesaurus available on STN
 NEWS  5  JAN 16  WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
 NEWS  6  JAN 22  CA/CAplus updated with revised CAS roles
 NEWS  7  JAN 22  CA/CAplus enhanced with patent applications from India
 NEWS  8  JAN 29  PHAR reloaded with new search and display fields
 NEWS  9  JAN 29  CAS Registry Number crossover limit increased to 300,000 in
                  multiple databases
 NEWS 10  FEB 15  PATDPASPC enhanced with Drug Approval numbers
 NEWS 11  FEB 15  RUSSIAPAT enhanced with pre-1994 records
 NEWS 12  FEB 23  KOREAPAT enhanced with IPC 8 features and functionality
 NEWS 13  FEB 26  MEDLINE reloaded with enhancements
 NEWS 14  FEB 26  EMBASE enhanced with Clinical Trial Number field
 NEWS 15  FEB 26  TOXCENTER enhanced with reloaded MEDLINE
 NEWS 16  FEB 26  IFICDB/IFIPAT/IFIUDB reloaded with enhancements
 NEWS 17  FEB 26  CAS Registry Number crossover limit increased from 10,000
                  to 300,000 in multiple databases
 NEWS 18  MAR 15  WPIDS/WPIX enhanced with new FRAGHITSTR display format
 NEWS 19  MAR 16  CASREACT coverage extended
 NEWS 20  MAR 20  MARPAT now updated daily
 NEWS 21  MAR 22  LWPI reloaded
 NEWS 22  MAR 30  RDISCLOSURE reloaded with enhancements
 NEWS 23  APR 02  JICST-EPLUS removed from database clusters and STN
 NEWS 24  APR 30  GENBANK reloaded and enhanced with Genome Project ID field
 NEWS 25  APR 30  CHEMCATS enhanced with 1.2 million new records
 NEWS 26  APR 30  CA/CAplus enhanced with 1870-1889 U.S. patent records
 NEWS 27  APR 30  INPADOC replaced by INPADOCDB on STN
 NEWS 28  MAY 01  New CAS web site launched

 NEWS EXPRESS  NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
```



```
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:59:55 ON 08 MAY 2007

=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 09:00:01 ON 08 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    7 MAY 2007  HIGHEST RN 934385-16-7
DICTIONARY FILE UPDATES:   7 MAY 2007  HIGHEST RN 934385-16-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10.574688\form1.str
```



```
chain nodes :
10  16  17  18  19  20  27  28
ring nodes :
1  2  3  4  5  6  7  8  9  11  12  13  14  15  21  22  23  24  25  26
chain bonds :
7-10  10-12  15-16  16-17  17-18  17-27  18-19  19-20  20-22  20-28
ring bonds :
1-2  1-6  1-9  2-3  3-4  4-5  5-6  6-7  7-8  8-9  11-12  11-15  12-13  13-14  14-15
21-22  21-26  22-23  23-24  24-25  25-26
exact/norm bonds :
1-9  6-7  7-8  8-9  10-12  11-12  11-15  12-13  13-14  14-15  15-16  16-17  17-27
18-19  19-20  20-28
```



```
exact bonds :
7-10  17-18  20-22
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  21-22  21-26  22-23  23-24  24-25  25-26

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:CLASS
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:CLASS  17:CLASS  18:CLASS  19:CLASS  20:CLASS
21:Atom
22:Atom  23:Atom  24:Atom  25:Atom  26:Atom  27:CLASS  28:CLASS



L1      STRUCTURE UPLOADED

=>

=> d
L1 HAS NO ANSWERS
L1              STR
```



```
Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 09:00:19 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       14 TO ITERATE

100.0% PROCESSED       14 ITERATIONS                              1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           56 TO       504
PROJECTED ANSWERS:               1 TO        80

L2            1 SEA SSS SAM L1

=> d

L2   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2007 ACS on STN
RN   850414-10-7  REGISTRY
ED   Entered STN:  13 May 2005
CN   Carbamic acid, [2-[[[2-[[(3R)-1-[(6-methyl-1H-indol-3-yl)methyl]-3-
     pyrrolidinyl]amino]-2-oxoethyl]amino]carbonyl]-4-(trifluoromethoxy)phenyl]-
```



```
     , phenylmethyl ester (9CI)  (CA INDEX NAME)
FS   STEREOSEARCH
MF   C32 H32 F3 N5 O5
SR   CA
LC   STN Files:   CA, CAPLUS

Absolute stereochemistry.
```



```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

              1 REFERENCES IN FILE CA (1907 TO DATE)
              1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> file hcaplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         2.40       2.61

FILE 'HCAPLUS' ENTERED AT 09:00:31 ON 08 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 8 May 2007  VOL  ISS  ISS
FILE LAST UPDATED: 7 May 2007  (20070507/ED)
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 8 May 2007  VOL 146 ISS 20
FILE LAST UPDATED: 1 May 2007  (20070501/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate

=> s l2
L3            1 L2

=> d ibib abs hitstr
```

L3 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:362059 HCAPLUS Full-text
DOCUMENT NUMBER: 142:430130
TITLE: Preparation of aminopyrrolidine derivatives as chemokine receptor antagonists
INVENTOR(S): Takeyasu, Takumi; Koga, Masahiro; Sato, Yoshiki
PATENT ASSIGNEE(S): Teijin Pharma Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| JP 2005112787 | A | 20050428 | JP 2003-349319 | 20031008 |
| PRIORITY APPLN. INFO.: | | | JP 2003-349319 | 20031008 |

OTHER SOURCE(S): MARPAT 142:430130
GI



I



II



III

AB The derive. I [R11 = H, C1-6 alkyl, C2-7 alkanoyl; R12, R14-R17 = H, halo, C1-6 (halo)alkyl, C1-6 (halo)alkoxy, OH, C2-7 alkoxycarbonyl; R1, R2 = H; R23-R26 = H, halo, C1-6 (halo)alkyl, C1-6 (halo)alkoxy, OH; R3 = H, C1-6 alkyl] or their salts, useful as chemokine receptor antagonists for prevention/treatment of diseases involving infiltration of monocytes, lymphocytes, etc., into tissues (no data), are prepared by condensation of II (R11, R12, R14-R17 = same as above) with III (R1, R2 = H, amino-protecting group; NR1R2 may be cyclyl; R3, R23-R26 = same as above) and optionally deprotection of the NR1R2 group. Thus, a mixture of THF, (R)-3-amino-1-(6-methylindol-3-ylmethyl)pyrrolidine (0.550 g, preparation given), 2-(2-tert-butoxycarbonylamino-5-trifluoromethoxybenzamido)acetic acid (0.757 g), 1-hydroxy-1,2,3-benzotriazole, and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, and Et3N was stirred at 45° for 20 h to give 1.51 g (R)-3-[2-(2-tert-butoxycarbonylamino-5- trifluoromethoxybenzamido)acetamido]-1-(6-methylindol-3- ylmethyl)pyrrolidine. This compound (17.688 g) was dissolved in MeOH and reacted treated HCl/1,4-dioxane at 40° for 20 h to give 13.54 g (R)-3-[2-(2-amino-5-trifluoromethoxybenzamido)acetamido]-1-(6-methylindol- 3-ylmethyl)pyrrolidine.
IT 850414-10-7P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of [(aminobenzamido)acetamido]-N-(indolylmethyl)pyrrolidines as chemokine receptor antagonists from (indolylmethyl)aminopyrrolidines and (aminobenzamido)acetic acids)
RN 850414-10-7 HCAPLUS
CN Carbamic acid, [2-[[[2-[[(3R)-1-[(6-methyl-1H-indol-3-yl)methyl]-3-pyrrolidinyl]amino]-2-oxoethyl]amino]carbonyl]-4-(trifluoromethoxy)phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





=> file reg

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 13.07 | 15.68 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
| CA SUBSCRIBER PRICE | -0.78 | -0.78 |

FILE 'REGISTRY' ENTERED AT 09:02:13 ON 08 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 MAY 2007 HIGHEST RN 934385-16-7
DICTIONARY FILE UPDATES: 7 MAY 2007 HIGHEST RN 934385-16-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s l1 sss full



FULL SEARCH INITIATED 09:02:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 279 TO ITERATE

100.0% PROCESSED 279 ITERATIONS 16 ANSWERS
SEARCH TIME: 00.00.01

L4 16 SEA SSS FUL L1

=> d scan

L4 16 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Indole-6-carboxylic acid, 3-[[(3R)-3-[[[[2-amino-5-(trifluoromethyl)benzoyl]amino]acetyl]amino]-1-pyrrolidinyl]methyl]-, methyl ester (9CI)
MF C25 H26 F3 N5 O4

Absolute stereochemistry.



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file hcaplus

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 172.10 | 187.78 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
| CA SUBSCRIBER PRICE | 0.00 | -0.78 |

FILE 'HCAPLUS' ENTERED AT 09:02:31 ON 08 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


FILE COVERS 1907 - 8 May 2007 VOL ISS ISS
FILE LAST UPDATED: 7 May 2007 (20070507/ED)
held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.


FILE COVERS 1907 - 8 May 2007 VOL 146 ISS 20



FILE LAST UPDATED: 1 May 2007 (20070501/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate

=> s l4 not l3
10 L4
L5 9 L4 NOT L3

=> d ibib abs hitstr

L5 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1096884 HCAPLUS Full-text
DOCUMENT NUMBER: 145:426031
TITLE: Crystal form of aminopyrrolidine derivative
INVENTOR(S): Takeyasu, Takumi; Sato, Yoshinori; Kawana, Asahi; Takahashi, Yuji; Ishikawa, Yuji; Suda, Kaoru
PATENT ASSIGNEE(S): Teijin Pharma Limited, Japan
SOURCE: PCT Int. Appl., 37pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2006109836 | A1 | 20061019 | WO 2006-JP307784 | 20060406 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |

PRIORITY APPLN. INFO.: JP 2005-110854 A 20050407
AB Two crystal forms of (R)-3-[2-(2-amino-5-trifluoromethoxybenzamido)acetami do]-1-(6-methylindol-3-ylmethyl)pyrrolidine (I) which exhibit specific x-ray powder diffraction patterns or IR absorption spectra, amorphous form thereof, a pharmaceutical composition containing the crystal or amorphous form as an active ingredient, as well as methods for preparing them are provided. To I was added EtOH, and the solution was heated at 70°. The solution was colled and the precipitated crystals were filtered.
IT 308362-58-5
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(crystal form of aminopyrrolidine derivative)
RN 308362-58-5 HCAPLUS
CN Benzamide, 2-amino-N-[2-[[(3R)-1-[(6-methyl-1H-indol-3-yl)methyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-5-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitstr 2-9

L5 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1329006 HCAPLUS Full-text
DOCUMENT NUMBER: 144:69721
TITLE: Method for producing acetamidopyrrolidine derivatives and intermediates therefor
INVENTOR(S): Kawana, Asahi; Takeyasu, Takumi; Hazato, Atsuo
PATENT ASSIGNEE(S): Teijin Pharma Limited, Japan
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2005121081 | A1 | 20051222 | WO 2005-JP11187 | 20050613 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2005252112 | A1 | 20051222 | AU 2005-252112 | 20050613 |
| CA 2570179 | A1 | 20051222 | CA 2005-2570179 | 20050613 |
| EP 1760075 | A1 | 20070307 | EP 2005-751221 | 20050613 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR | | | | |

PRIORITY APPLN. INFO.: JP 2004-175158 A 20040614
JP 2004-175159 A 20040614
WO 2005-JP11187 W 20050613

OTHER SOURCE(S): MARPAT 144:69721
GI





AB The title compds. I [R1 = H, alkyl; R13 - R16 = H, halo, alkyl, etc.; a proviso is given] are prepared by reaction of 1-benzyl-3-aminopyrrolidine with nitrobenzamidoacetic acid derivs. The title compds. are intermediates for chemokine receptor antagonists. Thus, a mixture of (2-nitro-5-trifluoromethoxybenzamido)acetic acid, (R)-1-benzyl-3-aminopyrrolidine, 1-hydroxy-1,2,3-benzotriazole, and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide HCl salt in Et acetate was stirred at 40°C for 4 h to give (R)-3-[2-(2-nitro-5- trifluoromethoxybenzamido)acetamido]-1-benzylpyrrolidine.

IT 308362-58-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(method for producing acetamidopyrrolidine derivs. via reaction of aminopyrrolidine derivs. with nitrobenzamidoacetic acid derivs.)

RN 308362-58-5 HCAPLUS
CN Benzamide, 2-amino-N-[2-[[(3R)-1-[(6-methyl-1H-indol-3-yl)methyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-5-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:346983 HCAPLUS Full-text
DOCUMENT NUMBER: 142:392285
TITLE: Process for producing aminopyrrolidine derivative and intermediate compound
INVENTOR(S): Takeyasu, Takumi; Sato, Yoshinori; Imai, Minoru; Sakai, Mitsuru; Manabe, Kenji; Matsumoto, Yoshiyuki; Takeuchi, Susumu; Kawana, Asahi; Koga, Masahiro; Asahita, Mitsuharu
PATENT ASSIGNEE(S): Teijin Pharma Limited, Japan
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|

Instant



| | | | | |
|---|---|---|---|---|
| WO 2005035493 | A1 | 20050421 | WO 2004-JP15186 | 20041007 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2004279721 | A1 | 20050421 | AU 2004-279721 | 20041007 |
| CA 2542012 | A1 | 20050421 | CA 2004-2542012 | 20041007 |
| EP 1676837 | A1 | 20060705 | EP 2004-792414 | 20041007 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| CN 1863769 | A | 20061115 | CN 2004-80029562 | 20041007 |
| BR 2004015018 | A | 20061128 | BR 2004-15018 | 20041007 |
| US 2007073064 | A1 | 20070329 | US 2006-574688 | 20060405 |

PRIORITY APPLN. INFO.: JP 2003-349318 A 20031008
JP 2003-350439 A 20031009
JP 2003-350441 A 20031009
WO 2004-JP15186 W 20041007

OTHER SOURCE(S): MARPAT 142:392285
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB There is disclosed a process for industrially producing an aminopyrrolidine derivative represented by the following formula (I) [R3 = H, C1-6 alkyl; R11 = H, C1-6 alkyl, C2-7 alkanoyl; R12, R14, R15, R17 = H, halo, each optionally halogenated C1-6 alkyl or C1-6 alkoxy, C2-7 alkoxycarbonyl; R23, R24, R25, R26 = H, halogeno, each optionally halogenated C1-6 alkyl or C1-6 alkoxy, hydroxy, C2-7 alkoxycarbonyl] and an intermediate thereof, e.g. (II). The compound I has antagonistic activity against a chemokine receptor. Thus, 5.07 g (R)-3-[2-[(2-(tert- butoxycarbonylamino)-5-trifluoromethoxybenzoyl]amino]acetamido]pyrrolidine (III) and 1.98 g 6-methylgramine were dissolved in 100 mL 2-propanol, heated at 95° with stirring while distilling away the solvent under slightly reduced pressure to give a residue upon which the same procedure was repeated four more times. The final reside was treated with 100 mL EtOAc and the resulting solution was washed with 100 mL 1 M aqueous NaOH solution and then twice with saturated aqueous NaCl solution, and dried over anhydrous Na2SO4 to give, after distilling away the solvent, 6.07 g (R)-3-[2-[[2-(tert- butoxycarbonylamino)-5-trifluoromethoxybenzoyl]amino]acetamido]-1-[(6- methylindol-3-yl)methyl]pyrrolidine (IV) (R = Boc). IV (6.07 g) was treated with 30 mL 10% HCl/MeOH, stirred at 50° for 2 h and treated with 120 mL 2 M HCl and 120 mL EtOAc to give, after workup, 3.49 g (R)-3-[2-[(2-amino-5-trifluoromethoxybenzoyl)amino]acetamido]-1-[(6- methylindol-3-yl)methyl]pyrrolidine IV (R = H).

IT 308362-58-5P, (R)-3-[2-[(2-Amino-5-trifluoromethoxybenzoyl)amino]acetamido]-1-[(6-methylindol-3-yl)methyl]pyrrolidine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(process for producing aminopyrrolidine derivative as chemokine receptor antagonist and intermediates thereof)

RN 308362-58-5 HCAPLUS
CN Benzamide, 2-amino-N-[2-[[(3R)-1-[(6-methyl-1H-indol-3-yl)methyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-5-(trifluoromethoxy)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



IT 308362-53-0P, (R)-3-[2-[(2-Amino-5-trifluoromethoxybenzoyl)amino]acetamido]-1-[(indol-3-yl)methyl]pyrrolidine 850140-82-8P, (R)-3-[2-[[2-(tert-Butoxycarbonylamino)-5-trifluoromethoxybenzoyl]amino]acetamido]-1-[(6-methylindol-3-yl)methyl]pyrrolidine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for producing aminopyrrolidine derivative as chemokine receptor antagonist and intermediates thereof)

RN 308362-53-0 HCAPLUS
CN Benzamide, 2-amino-N-[2-[[(3R)-1-(1H-indol-3-ylmethyl)-3-pyrrolidinyl]amino]-2-oxoethyl]-5-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850140-82-8 HCAPLUS
CN Carbamic acid, [2-[[[2-[[(3R)-1-[(6-methyl-1H-indol-3-yl)methyl]-3-pyrrolidinyl]amino]-2-oxoethyl]amino]carbonyl]-4-(trifluoromethoxy)phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:237356 HCAPLUS Full-text
DOCUMENT NUMBER: 136:263090
TITLE: Preparation of cyclic amine derivatives for inhibition of the action of chemokines such as MIP-1α and/or MCP-1 on target cells
INVENTOR(S): Shiota, Tatsuki; Kataoka, Ken-Ichiro; Imai, Minoru; Tsutsumi, Takaharu; Sudoh, Masaki; Sogawa, Ryo; Morita, Takuya; Hada, Takahiko; Muroga, Yumiko; Takenouchi, Osami; Furuya, Minoru; Endo, Noriaki; Tarby, Christine M.; Moree, Wilna; Teig, Steven
PATENT ASSIGNEE(S): Teijin Limited, Japan; Dupont Pharmaceuticals Research Laboratories
SOURCE: U.S., 364 pp., Cont. of U.S. Ser. No. 554,562.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 6362177 | B1 | 20020326 | US 2001-905078 | 20010716 |
| US 6451842 | B1 | 20020917 | US 2000-554562 | 20000516 |
| US 6410566 | B1 | 20020625 | US 2001-905077 | 20010716 |
| PRIORITY APPLN. INFO.: | | | US 2000-554562 | A3 20000516 |
| | | | US 1997-972484 | B1 19971118 |
| | | | US 1998-55285 | B1 19980406 |
| | | | US 1998-133434 | B1 19980813 |
| | | | WO 1998-US23254 | W 19981117 |

OTHER SOURCE(S): MARPAT 136:263090
GI



I



II

AB The title compds. [I; R1 = (un)substituted Ph, cycloalkyl, heteroaryl, etc.; R2 = H, alkyl, alkoxycarbonyl, etc.; j = 0-2; k = 0-2; m = 3-4 and k+m = 5 or 6; n = 0-1; R3 = H, alkyl; R4, R5 = H, OH, Ph, etc.; p, q = 0-1; G = CO, SO, CO2, etc.; R6 = Ph, cycloalkyl, cycloalkenyl, etc.] and their pharmaceutically acceptable acid addition salts which inhibit the action of chemokines such as MIP-1α and/or MCP-1 on target cells and may be useful as a therapeutic drug and/or preventative drug in diseases, such as atherosclerosis, rheumatoid arthritis, and the like where blood monocytes and lymphocytes infiltrate into tissues, were prepared Thus, reaction of N-benzoylglycine with 3-amino-1-(4- chlorobenzyl)pyrrolidine.2HCl in the presence of 3-ethyl-1-[3-(dimethylaminopropyl)]carbodiimide.HCl, 1-hydroxybenzotriazole and Et3N in CHCl3 afforded 95% II which showed 50-80% inhibition of MIP-1α binding to THP-1 cells at 10 μM.

IT 226248-82-4P, 1H-Indole-6-carboxylic acid, 3-[[(3R)-3-[[[[2-amino-5-(trifluoromethyl)benzoyl]amino]acetyl]amino]-1-pyrrolidinyl]methyl]-, methyl ester 226248-83-5P, Benzamide, N-[2-[[(3R)-1-[(1-acetyl-1H-indol-3-yl)methyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-2-amino-5-(trifluoromethyl)-
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclic amine derivs. for inhibition of action of chemokines such as MIP-1α and/or MCP-1 on target cells)

RN 226248-82-4 HCAPLUS
CN 1H-Indole-6-carboxylic acid, 3-[[(3R)-3-[[[[2-amino-5-(trifluoromethyl)benzoyl]amino]acetyl]amino]-1-pyrrolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 226248-83-5 HCAPLUS
CN Benzamide, N-[2-[[(3R)-1-[(1-acetyl-1H-indol-3-yl)methyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-2-amino-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:435041 HCAPLUS Full-text
DOCUMENT NUMBER: 135:33431
TITLE: Preparation of cycloamine as CCR5 receptor antagonists
INVENTOR(S): Shiota, Tatsuki; Yokoyama, Tomonori; Kamimura, Takashi
PATENT ASSIGNEE(S): Teijin Limited, Japan
SOURCE: PCT Int. Appl., 271 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001042208 | A1 | 20010614 | WO 2000-JP8627 | 20001206 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2393757 | A1 | 20010614 | CA 2000-2393757 | 20001206 |
| AU 200117314 | A | 20010618 | AU 2001-17314 | 20001206 |
| AU 778173 | B2 | 20041118 | | |
| EP 1238970 | A1 | 20020911 | EP 2000-979945 | 20001206 |
| EP 1238970 | B1 | 20061122 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| AT 346042 | T | 20061215 | AT 2000-979945 | 20001206 |
| US 2007010509 | A1 | 20070111 | US 2002-148831 | 20020605 |
| PRIORITY APPLN. INFO.: | | | JP 1999-348778 | A 19991208 |
| | | | WO 2000-JP8627 | W 20001206 |

OTHER SOURCE(S): MARPAT 135:33431
GI



I

AB Therapeutic or preventive agents for β-chemokine receptor CCR5-related diseases such as AIDS, rheumatoid arthritis, and nephritis, containing as the active ingredient, cyclic amine derivs. such as piperidine and pyrrolidine derivs. of general formula [I; R1 = (un)substituted Ph, C3-8 cycloalkyl, or aromatic heterocyclyl containing 1-3 heteroatoms of O, S, and/N wherein Ph and aromatic heterocyclyl group is optionally condensed to benzene ring or heterocyclyl ring containing 1-3 heteroatoms of O, S, and/N to from an (un)substituted condensed ring; R2 = H, (un)substituted C1-6 alkyl or Ph, C2-7 alkoxycarbonyl, HO; j, k = 0-2; m = 2-4; n = 0,1; R3 = H, (un)substituted phenyl-optionally substituted C1-6 alkyl; R4, R5 = H, HO, Ph, (un)substituted C1-6 alkyl; or R4 and R5 together represent a 3-6-membered ring cyclic hydrocarbyl; p, q = 0,1; G = CO, SO2, CO2, NR7CO, CONR7, NHCONH, NHC(S)NH, NR7SO2, SO2 NR7, NHCO2, O2CNH (wherein R7 = H, C1-6 alkyl; or R7 and R5 together form C2-5 alkylene); R6 = (un)substituted C3-8 cycloalkyl, C3-6 cycloalkenyl, Ph, benzyl, or aromatic heterocyclyl containing 1-3 heteroatoms of O, S, and/N, wherein Ph, benzyl, and aromatic heterocyclyl are optionally condensed with benzene ring or aromatic heterocyclyl group containing 1-3 heteroatoms of O, S, and/N to form an (un)substituted condensed ring], pharmaceutically acceptable adducts of the same with acids, or pharmaceutically acceptable adducts thereof with C1-6 alkyl, are described. Above CCR5-related diseases include diseases accompanied by destruction of cartilage or bone (in particular chronic rheumatoid arthritis), nephritis or kidney diseases (in particular glomerulonephritis, interstitial nephritis, or nephrosis), demyelinating diseases (in particular multiple sclerosis), post-transplant rejection, host-vs.-graft diseases (GVHD), diabetes, chronic obstructive pulmonary diseases (COPD), bronchial asthma, atopic dermatitis, sarcoidosis, fibrosis, arteriosclerosis, psoriasis, and inflammatory bowel diseases. Thus, 3-(trifluoromethylthio)benzoic acid was condensed with (R)-1-(4-chlorobenzyl)-3-(glycylamino)pyrrolidine using diisopropylcarbodiimide and HOBt in tert-butanol and CHCl3 at room temperature for 15 h to give (R)-1-(4-chlorobenzyl)-3-[[N-(3- (trifluoromethylthio)benzoyl)glycyl]amino]pyrrolidine (II). II and (R)-1-(6-methyl-3-indolylmethyl)-3-[[N-(2-amino-5-(trifluoromethoxy)benzoyl)glycyl]amino]pyrrolidine 10 μM in vitro inhibited by 20-50% and >80%, resp., the binding of [125I]macrophage inflammatory protein-1α (MIP-1α) to CCR5-receptor expressed in CHO cells.

IT 226248-83-5P 343930-38-1P 343930-39-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cycloamine as CCR5 receptor antagonists for therapeutics or remedies of β-chemokine receptor CCR5-related diseases such as AIDS, rheumatoid arthritis, and nephritis)

RN 226248-83-5 HCAPLUS
CN Benzamide, N-[2-[[(3R)-1-[(1-acetyl-1H-indol-3-yl)methyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-2-amino-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 343930-38-1 HCAPLUS
CN Benzamide, N-[2-[[(3R)-1-[(1-acetyl-1H-indol-3-yl)methyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-2-amino-5-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 343930-39-2 HCAPLUS
CN Benzamide, N-[2-[[(3R)-1-[(1-acetyl-6-methyl-1H-indol-3-yl)methyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-2-amino-5-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 9 'HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:114982 HCAPLUS Full-text
DOCUMENT NUMBER: 134:173028
TITLE: Cyclic amine CCR3 antagonists
INVENTOR(S): Shiota, Tatsuki; Sudoh, Masaki; Yokoyama, Tomonori; Muroga, Yumiko; Kamimura, Takashi; Nakanishi, Akinobu
PATENT ASSIGNEE(S): Teijin Ltd., Japan
SOURCE: PCT Int. Appl., 263 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001010439 | A1 | 20010215 | WO 2000-JP5260 | 20000804 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2378499 | A1 | 20010215 | CA 2000-2378499 | 20000804 |
| EP 1201239 | A1 | 20020502 | EP 2000-950006 | 20000804 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | |
| AU 779610 | B2 | 20050203 | AU 2000-63193 | 20000804 |
| PRIORITY APPLN. INFO.: | | | JP 1999-220864 A | 19990804 |
| | | | WO 2000-JP5260 W | 20000804 |

OTHER SOURCE(S): MARPAT 134:173028

AB Drugs containing as the active ingredient cyclic amine derivs. represented by general formula (Markush's structure given), pharmaceutically acceptable acid addition salts thereof or pharmaceutically acceptable C1-6 alkyl adducts thereof. These drugs are efficacious in preventing and treating diseases in which CCR3 participates such as asthma and allergic rhinitis.

IT 226248-83-5
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclic amine CCR3 antagonists as antiasthmatics and allergy inhibitors)

RN 226248-83-5 HCAPLUS
CN Benzamide, N-[2-[[(3R)-1-[(1-acetyl-1H-indol-3-yl)methyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-2-amino-5-(trifluoromethyl)- (9CI) (CA



INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:824101 HCAPLUS Full-text
DOCUMENT NUMBER: 134:5154
TITLE: Preparation of cyclic amine derivatives as remedies or preventives for diseases in association with chemokines or chemokine receptors
INVENTOR(S): Shiota, Tatsuki; Miyagi, Fuminori; Kamimura, Takashi; Ohta, Tomohiro; Takano, Yasuhiro; Horiuchi, Hideki
PATENT ASSIGNEE(S): Teijin Limited, Japan
SOURCE: PCT Int. Appl., 405 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2000069432 | A1 | 20001123 | WO 2000-JP3203 | 20000518 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2373942 | A1 | 20001123 | CA 2000-2373942 | 20000518 |
| EP 1179341 | A1 | 20020213 | EP 2000-927808 | 20000518 |
| EP 1179341 | B1 | 20051109 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| NZ 515374 | A | 20040924 | NZ 2000-515374 | 20000518 |
| AU 779954 | B2 | 20050224 | AU 2000-46147 | 20000518 |
| AT 308985 | T | 20051115 | AT 2000-927808 | 20000518 |
| ES 2250132 | T3 | 20060416 | ES 2000-927808 | 20000518 |
| NO 2001005599 | A | 20011116 | NO 2001-5599 | 20011116 |
| PRIORITY APPLN. INFO.: | | | JP 1999-175856 A | 19990518 |
| | | | JP 1999-251464 A | 19990906 |
| | | | WO 2000-JP3203 W | 20000518 |

OTHER SOURCE(S): MARPAT 134:5154
GI





I

AB Remedies or preventives for diseases in association with chemokines such as MIP-1α and/or MCP-1 or chemokine receptors such as CCR1 or CCR2 contain as the active ingredient N-acyl-amino acid N-cyclic amino or N-cyclic aminoalkyl-amide derivs. represented by general formula [I; (un)substituted Ph, C3-8 cycloalkyl, aromatic heterocyclyl containing 1-3 heteroatoms selected from O, S, and/or N; R2 = H, (un)substituted C1-6 alkyl, C2-7 alkoxycarbonyl, HO, (un)substituted Ph; p1, m1 = 0-2; m = 2-4; n = 0,1; R3 = H, (un)substituted C1-6 alkyl; R4, R5 = H, OH, (un)substituted Ph or C1-6 alkyl; or R4 and R5 are combined together to form a 3- to 5-membered hydrocarbyl; p, q = 0,1; G = CO, SO2, CO2, NR7CO, CONR7, NR7SO2, or SO2NR7, NHCONH, NHCSNH, NH CO2, O2CNH; R7 = H, C1-6 alkyl; or R7 and R5 are combined together to form C2-5 alkylene; R6 = (un)substituted Ph, C3-8 cycloalkyl, C3-6 cycloalkenyl, CH2Ph, or aromatic heterocyclyl containing 1-3 heteroatoms selected from O, S, and/or N, wherein Ph, CH2Ph, or aromatic heterocyclyl group is optionally fused with (un)substituted benzene or aromatic heterocyclyl containing 1-3 heteroatoms selected from O, S, and/or N], pharmaceutically acceptable acid-adducts thereof, or pharmaceutically acceptable C1-6 alkyl-adducts thereof. The above diseases include destruction of bone or cartilage (e.g. arthritis, rheumatoid arthritis, osteoarthritis, osteoporosis, injury, and tumor), nephritis, kidney diseases, glomerulus or interstitial nephritis, nephrotic syndrome, demyelinating disease, or multiple sclerosis. Thus, N-3-ethoxybenzyl-D-methionine-N-[1-(4-chlorobenzyl)-4-piperazinylmethyl]amide in vitro inhibited the binding of human MIP-1α to THP-1 cells by >80% at 2 μM.

IT 226248-82-4P 226248-83-5P 308362-52-9P 308362-53-0P 308362-54-1P 308362-55-2P 308362-56-3P 308362-57-4P 308362-58-5P 308362-59-6P 308362-61-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclic amine derivs. as remedies or preventives for diseases in association with chemokines or chemokine receptors)

RN 226248-82-4 HCAPLUS
CN 1H-Indole-6-carboxylic acid, 3-[[(3R)-3-[[[[2-amino-5-(trifluoromethyl)benzoyl]amino]acetyl]amino]-1-pyrrolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 226248-83-5 HCAPLUS
CN Benzamide, N-[2-[[(3R)-1-[(1-acetyl-1H-indol-3-yl)methyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-2-amino-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 308362-52-9 HCAPLUS
CN Benzamide, 2-amino-N-[2-[[(3R)-1-(1H-indol-3-ylmethyl)-3-pyrrolidinyl]amino]-2-oxoethyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 308362-53-0 HCAPLUS
CN Benzamide, 2-amino-N-[2-[[(3R)-1-(1H-indol-3-ylmethyl)-3-pyrrolidinyl]amino]-2-oxoethyl]-5-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 308362-54-1 HCAPLUS
CN Benzamide, 2-amino-N-[2-[[(3R)-1-[(5-fluoro-1H-indol-3-yl)methyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-5-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 308362-55-2 HCAPLUS
CN Benzamide, 2-amino-N-[2-[[(3R)-1-[(5-chloro-1H-indol-3-yl)methyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-5-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 308362-56-3 HCAPLUS
CN Benzamide, 2-amino-N-[2-[[(3R)-1-[(5-methoxy-1H-indol-3-yl)methyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-5-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 308362-57-4 HCAPLUS
CN Benzamide, 2-amino-N-[2-[[(3R)-1-[(2-methyl-1H-indol-3-yl)methyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-5-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 308362-58-5 HCAPLUS
CN Benzamide, 2-amino-N-[2-[[(3R)-1-[(6-methyl-1H-indol-3-yl)methyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-5-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 308362-59-6 HCAPLUS
CN Benzamide, 2-amino-N-[2-[[(3R)-1-[(7-methyl-1H-indol-3-yl)methyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-5-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 308362-61-0 HCAPLUS
CN Benzamide, 2-amino-N-[2-[[(3R)-1-[(6-fluoro-1H-indol-3-yl)methyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-5-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:350650 HCAPLUS Full-text
DOCUMENT NUMBER: 131:18925
TITLE: Preparation of cyclic amine derivatives for inhibition of the action of chemokines such as MIP-1α and/or MCP-1 on target cells
INVENTOR(S): Shiota, Tatsuki; Kataoka, Kenichiro; Imai, Minoru; Tsutsumi, Takaharu; Sudoh, Masaki; Sogawa, Ryo; Morita, Takuya; Hada, Takahiko; Muroga, Yumiko; Takenouchi, Osami; Furuya, Monoru; Endo, Noriaki; Tarby, Christine M.; Moree, Wil A.; Teig, Steven L.
PATENT ASSIGNEE(S): Teijin Ltd., Japan; Combichem, Inc.
SOURCE: PCT Int. Appl., 374 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9925686 | A1 | 19990527 | WO 1998-US23254 | 19981117 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW | | | | |
| RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2309328 | A1 | 19990527 | CA 1998-2309328 | 19981117 |
| AU 9913741 | A | 19990607 | AU 1999-13741 | 19981117 |
| AU 744685 | B2 | 20020228 | | |
| EP 1030840 | A1 | 20000830 | EP 1998-957495 | 19981117 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| TR 200001399 | T2 | 20001121 | TR 2000-200001399 | 19981117 |
| HU 200004200 | A2 | 20010328 | HU 2000-4200 | 19981117 |
| BR 9814645 | A | 20010731 | BR 1998-14645 | 19981117 |
| EE 200000294 | A | 20010815 | EE 2000-294 | 19981117 |
| JP 2001523661 | T | 20011127 | JP 2000-521070 | 19981117 |
| JP 3786578 | B2 | 20060614 | | |
| RU 2216540 | C2 | 20031120 | RU 2000-112403 | 19981117 |
| CN 1496981 | A | 20040519 | CN 2002-2002118546 | 19981117 |
| EP 1535909 | A2 | 20050601 | EP 2005-75285 | 19981117 |
| EP 1535909 | A3 | 20050713 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY | | | | |
| EP 1553085 | A1 | 20050713 | EP 2005-75283 | 19981117 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, LV, FI, MK, CY | | | | |
| CN 1660815 | A | 20050831 | CN 2004-10082013 | 19981117 |
| PL 192083 | B1 | 20060831 | PL 1998-342207 | 19981117 |
| HR 2000000214 | A1 | 20011231 | HR 2000-214 | 20000413 |
| NO 2000002486 | A | 20000718 | NO 2000-2486 | 20000512 |
| BG 104441 | A | 20010131 | BG 2000-104441 | 20000516 |
| BG 64848 | B1 | 20060630 | | |
| US 6451842 | B1 | 20020917 | US 2000-554562 | 20000516 |
| PRIORITY APPLN. INFO.: | | | US 1997-972484 | A 19971118 |
| | | | US 1998-55285 | A 19980406 |
| | | | US 1998-133434 | A 19980813 |
| | | | CN 1998-811317 | A3 19981117 |
| | | | EP 1998-957495 | A3 19981117 |
| | | | WO 1998-US23254 | W 19981117 |

OTHER SOURCE(S): MARPAT 131:18925
GI



I



II

AB The title compds. [I; R1 = (un)substituted Ph, cycloalkyl, heteroaryl, etc.; R2 = H, alkyl, alkoxycarbonyl, etc.; j = 0-2; k = 0-2; m = 2-4; n = 0-1; R3 = H, alkyl; R4, R5 = H, OH< Ph, etc.; p = 0-1; q = 0-1; G = CO, SO, CO2, etc.; R6 = Ph, cycloalkyl, cycloalkenyl, etc.] and their pharmaceutically acceptable acid addition salts which inhibit the action of chemokines such as MIP-1α and/or MCP-1 on target cells and may be useful as a therapeutic drug and/or preventative drug in diseases, such as atherosclerosis, rheumatoid arthritis, and the like where blood monocytes and lymphocytes infiltrate into tissues, were prepared Thus, reaction of N-benzoylglycine with 3-amino-1-(4-chlorobenzyl)pyrrolidine.2HCl in the presence of 3-ethyl-1-[3-(dimethylaminopropyl)]carbodiimide.HCl, 1-hydroxybenzotriazole and Et3N in CHCl3 afforded 95% II which showed 50-80% inhibition of MIP-1α binding to THP-1 cells at 10 μM.

IT 226248-82-4P 226248-83-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclic amine derivs. for inhibition of the action of chemokines such as MIP-1α and/or MCP-1 on target cells)

RN 226248-82-4 HCAPLUS
CN 1H-Indole-6-carboxylic acid, 3-[[(3R)-3-[[[[2-amino-5-(trifluoromethyl)benzoyl]amino]acetyl]amino]-1-pyrrolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 226248-83-5 HCAPLUS
CN Benzamide, N-[2-[[(3R)-1-[(1-acetyl-1H-indol-3-yl)methyl]-3-pyrrolidinyl]amino]-2-oxoethyl]-2-amino-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:745183 HCAPLUS Full-text
DOCUMENT NUMBER: 130:14263
TITLE: Preparation of amino acid derivatives as protease inhibitors
INVENTOR(S): Marquis, Robert W.; Ru, Yu; Veber, Daniel F.
PATENT ASSIGNEE(S): Smithkline Beecham Corp., USA
SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9850534 | A1 | 19981112 | WO 1998-US9192 | 19980506 |
| W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| CA 2289010 | A1 | 19981112 | CA 1998-2289010 | 19980506 |
| AU 9872885 | A | 19981127 | AU 1998-72885 | 19980506 |
| EP 991753 | A1 | 20000412 | EP 1998-920274 | 19980506 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO | | | | |



| | | | | |
|---|---|---|---|---|
| BR 9808502 | A | 20000523 | BR 1998-8502 | 19980506 |
| TR 9902752 | T2 | 20000621 | TR 1999-2752 | 19980506 |
| HU 200001285 | A2 | 20000928 | HU 2000-1285 | 19980506 |
| JP 2001525809 | T | 20011211 | JP 1998-548418 | 19980506 |
| ZA 9803843 | A | 19981109 | ZA 1998-3843 | 19980507 |
| US 6369077 | B1 | 20020409 | US 1999-423325 | 19991104 |
| NO 9905433 | A | 19991105 | NO 1999-5433 | 19991105 |
| MX 9910260 | A | 20000430 | MX 1999-10260 | 19991108 |
| PRIORITY APPLN. INFO.: | | | US 1997-46865P | P 19970508 |
| | | | WO 1998-US9192 | W 19980506 |

OTHER SOURCE(S): MARPAT 130:14263
GI



I

AB Amino acid derivs. I [Y = aryl, NR1R2; R1 = R'', R''CO, R''CS, R''SO2, R''O2C, R''R'NCO, R''R'NCS; R2 = H, alkyl, alkenyl, arylalkyl, heterocyclylalkyl; R3 = H, alkenyl, alkynyl, heterocyclyl, aryl, (un)substituted alkyl; R4 = H, alkyl, alkenyl, arylalkyl, heterocyclylalkyl; R5 = R6NR'CHR7Z, arylalkyl, heterocyclylalkyl, adamantylcarbonyl, arylcarbonyl, heterocyclylcarbonyl; R6 = R'', R''CO, R''CS, R''SO2, R''O2C, R''R'NCO, R''R'NCS, R''O2CNR'CHR*CO; R7 = cycloalkylalkyl, arylalkyl, heterocyclylalkyl, arylalkoxy, heterocyclylalkoxy, (un)substituted alkyl; R* = H, alkyl, alkenyl, cycloalkylalkyl, arylalkyl, heterocyclylalkyl; R' = H, alkyl, alkenyl, arylalkyl, heterocyclylalkyl; R'' = H, alkyl, cycloalkylalkyl, arylalkyl, heterocyclylalkyl; Z = CO, CH2; X = (CH2)n, where n = 1, 2, 3] were prepared as protease inhibitors. Thus, 3-[[Nα-(2-quinolinecarbonyl)-L-leucinyl]amino]-1-[(2S)-4-methyl-2-[(benzyloxycarbonyl)amino]pentyl]pyrrol idine was prepared from 3-(tert-butoxycarbonylamino)pyrrolidine, Cbz-leucine, Boc-leucine, and quinaldic acid.

IT 215946-69-3P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid derivs. as protease inhibitors)

RN 215946-69-3 HCAPLUS
CN 2-Naphthalenecarboxamide, N-[(1S)-1-[[[(3S)-1-(1H-indol-3-ylmethyl)-3-pyrrolidinyl]amino]carbonyl]-3-methylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



```
=> FIL STNGUIDE
COST IN U.S. DOLLARS                        SINCE FILE      TOTAL
                                              ENTRY    SESSION
FULL ESTIMATED COST                             91.63     279.41

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)  SINCE FILE      TOTAL
                                              ENTRY    SESSION
CA SUBSCRIBER PRICE                             -7.02      -7.80

FILE 'STNGUIDE' ENTERED AT 09:12:46 ON 08 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May  4, 2007 (20070504/UP).

=> 9939
=>
=>
9939 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> log hold
COST IN U.S. DOLLARS                        SINCE FILE      TOTAL
                                              ENTRY    SESSION
FULL ESTIMATED COST                              3.00     282.41

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)  SINCE FILE      TOTAL
                                              ENTRY    SESSION
CA SUBSCRIBER PRICE                              0.00      -7.80

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 09:43:03 ON 08 MAY 2007
```